N-(2,3-dichlorophenyl)cyclohexanecarboxamide | 200709-97-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,3-dichlorophenyl)cyclohexanecarboxamide
• CAS: 200709-97-3
• 化学式: C₁₃H₁₅Cl₂NO
• 分子量: 272.17
• InChiKey: ZYPWKRVXNGLEMU-UHFFFAOYSA-N

物化性质

• 沸点：
  429.3±35.0 °C(Predicted)
• 密度：
  1.302±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer
  申请人：Cox Marc B.

  公开号：US10434075B2

  公开（公告）日：2019-10-08

  Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.

  本发明的实施方案包括通过向有需要的受试者施用有效量的 MJC13 来治疗乳腺癌的方法和组合物。
• PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
  申请人：Neckers Leonard M.

  公开号：US20120283215A1

  公开（公告）日：2012-11-08

  Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
• FKBP52 TARGETING AGENT PHARMACEUTICAL COMPOSITIONS
  申请人：THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV

  公开号：US20160030369A1

  公开（公告）日：2016-02-04

  Liposomes comprising an FKBP52 targeting agent (FTA) are disclosed. Pharmaceutical compositions comprising an FTA, a solvent, and a surfactant are disclosed. Pharmaceutical compositions comprising a cyclodextrin and/or a derivative thereof and an FTA are also disclosed. Method of detecting one or more compounds in a sample by liquid chromatography/tandem mass spectrometry (LC/MS/MS), methods of treating or preventing cancer, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), prostatitis, enlarged prostate, or insulin-independent diabetes, and methods of inhibiting spermatogenesis or fertilized oocyte implantation in a mammal are also provided.
• FKBP52-SPECIFIC ANDROGEN RECEPTOR INHIBITOR, MJC13, FOR USE IN TREATING BREAST CANCER
  申请人：Cox Marc B.

  公开号：US20170360725A1

  公开（公告）日：2017-12-21

  Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
• US8859207B2
  申请人：——

  公开号：US8859207B2

  公开（公告）日：2014-10-14